 |
| Click for OlympiA Clinical Trial video |
The study was reported in the June 3, 2021 New England Journal of Medicine.
The trial called "Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer," dubbed the OlympiA trial involved 1,836 patients from 420 cancer cancer centers across 23 countries.
The trial called "Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer," dubbed the OlympiA trial involved 1,836 patients from 420 cancer cancer centers across 23 countries.
Breast cancer patients with the BRCA mutations who had received prior treatment were randomly assigned to receive a new drug called a PARP inhibitor, olaparib (Lynparza®). After three years 85.9% of patients who received Olaparib survived free of recurrent breast cancers compared to 77.1% of those in the placebo group. Over the same period 87.5% of the Olaparib group remained free of distant metastatic cancer compared to 80.4% of the placebo group.
Overall there were 27 fewer deaths in Olaparib group compared to the placebo group.
The study was led by top breast cancer researchers Charles Geyer, MD at Houston Methodist Cancer Center, Judy Garber, MD, MPH at Dana Farber Cancer Institute, and Bella Kaufman, MD, of the Sheba Medical Center in Israel.
The study was funded by the US National Cancer Institute and AstraZeneca.
Source: Houston Methodist Cancer Center press release
Now! I'm finally free from the damn shit! Cancer. I can't just believe I'm totally cured at last! If you have never try natural herbs products this is what you, im recommended you to drubarlo here. and don't be deceive by people who choose to say the truth, that cancer don't have a cure meet him here Email drubarlohome@gmail.com OR add on whatsapp +2348119508814
ReplyDelete